REGN on Decifer

Why it ranks here

• It earns solid returns on the money it puts to work, around 9% and it turns most of its profit into real cash.
• Revenue is expected to grow about 11% a year, profits grew 5% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.

The current read

The evidence on REGN lines up on the supportive side: trading volume is unusually heavy as the stock rises today, so the move has real participation. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Regeneron Pharmaceuticals, Inc. sits in the biotech layer of the Healthcare, Biotech & Devices story.

Read the full REGN research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.